Heart and Blood Diseases

All Conditions

Behaviors and Mental Disorders

Thromboembolism

Venous Thromboembolism

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Quality of Life

Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).

Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.

Questionnaires

Cristhiam M. Rojas Hernandez, MD

Cristhiam M Rojas Hernandez, MD

Juan E Gomez-Mesa, MD

Carme Font, MD

: Juan J Lopez Nuñez, MD

The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VTE) that is related to cancer.

This is an investigational study. Up to 260 participants will be enrolled in this multicenter study. Up to 170 will take part in MD Anderson.

If you agree to take part in this study, you will complete 2 questionnaires either at an already-scheduled clinic visit or over the phone at the time you join this study and then about 30 days, 3 months, 6 months, and 12 months after that. These questionnaires will be about your quality of life and experiences with treatment for VTE. It should take less than 10 minutes to complete the questionnaires each time.

Information from your medical record may also be collected at these time points.

Your participation will be over after the last questionnaires are completed at about 12 months after you enroll in the study.

Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

Measurement of Adherence and Health-related Quality of Life, and Health-Care Resource Utilization During Anticoagulation Therapy in Cancer-Related Venous Thromboembolism (VTE)

Adherence categorized as "adequate" versus "non-adequate" based on the Morisky scale.

The HRQL variables measured using a deep venous thrombosis quality of life questionnaire: DVTQOL.

M.D. Anderson Cancer Center

Neoplasms

Digestive System Diseases

Rare Diseases

Stomach Neoplasms

Stomach Cancer

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Heparin

Calcium heparin

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

another arm include intermittent pneumatic compression plus low molecular weight heparin

40mg 12 hours before surgery and 12 hours later surgery

low molecular weight heparin

Kyo Young Song, M.D.

This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.

Venous thromboembolism (VTE) is common and often fatal complication in patients with cancer.

Gastric cancer is the most frequent cancer in Korea.

The incidence of VTE would be increased in patients with gastric cancer, especially associated surgery.

However, the incidence and optimal prophylactic method associated with cancer surgery are not well studied in Asian patients.

Most Korean surgeon concerns regarding the increased postoperative bleeding associated with low molecular weight heparin(LMWH)prophylaxis.

The incidence and adverse event will be examined to define the optimal prophylactic method of VTE in surgical patients with gastric cancer.

Optimal Prophylactic Method of Venous Thromboembolism (VTE)

Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients

The incidence of VTE between mechanical method only group and mechnical plus LMWH group.

The adverse event such as bleeding will also be compared.

The Catholic University of Korea

Associate Professor

Gland and Hormone Related Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Venous Thrombosis

Pancreatic Neoplasms

Pulmonary Embolism

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Gastrointestinal Agents

Pancrelipase

Pancreatin

Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.

5000 units subcutaneous, by injection under the skin, daily for 16 weeks

Saroj Vadhan-Raj, MD

The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy. Some patients will receive dalteparin and some will receive no study drug.

The safety of dalteparin will also be studied.

Study Drug:

Dalteparin is designed to thin the blood and block blood from clotting. This may lower the risk of VTE.

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) into 1 of 2 groups. There is an equal chance of being assigned to either group.

Group 1 will receive dalteparin.

Group 2 will not receive a study drug.

During this study, all study participants will be routinely checked for VTE by ultrasounds and CT scans.

You may also receive standard therapies for preventing VTE. This may include blood-thinning drugs while you are in the hospital, getting up and moving around at least 5 times per day, and/or wearing special stockings or boot-like devices designed to put pressure on the feet.

Genetic Research Testing:

Before starting your therapy (at baseline), blood (about 1 teaspoon) will be drawn and stored for genetic testing. Researchers want to use DNA (the genetic material in cells) to look for markers that may be related to having a high risk for developing blood clots. The samples will be processed and stored at MD Anderson. Once this study ends, the DNA will be tested further in Dr. Futreal's laboratory and/or may be shipped outside to Illumina Sequencing Services (San Diego, CA) for genetic research. The samples will be deidentified before shipping.

Before your samples are sent to the outside laboratory for banking, your name and any personal identifying information will be coded to protect your privacy. The outside researchers will not have access to the codes that link the samples to your identity.

Study Drug Administration:

If you are in Group 1, you will receive dalteparin by injection under your skin, once a day for 16 weeks. You and/or your caregiver will be taught how to perform injections.

Study Visits:

At every study visit, the following tests and procedures will be performed:

* You will have a physical exam, including measurement of your vital signs (blood pressure, heart rate, temperature and breathing rate).
* Your medical history will be recorded.

About every 2 weeks after chemotherapy starts until Week 16, blood (about 2 teaspoons) will be drawn for routine tests. This test may be repeated more often if the doctor decides it is needed.

Before each new cycle of chemotherapy during Weeks 1-16, blood (about 2 teaspoons) will be drawn for routine tests to check the function of your liver and kidneys.

At Weeks 8 and 16 (+/- 7 days), the following procedures will be performed:

* You will have an ultrasound of your legs to check for blood clots.
* If the doctor decides it is needed, you will have CT scans to check the status of the cancer. Researchers will also check your chest CT scans to look for blood clots in the lungs.

Length of Study Participation:

You may remain on study for up to 16 weeks. You will be taken off study early if blood clots occur or you experience intolerable side effects.

Follow-Up Phone Calls:

This study has a 3-year follow-up period. In Year 1, you will receive a follow-up phone call from the study staff in the first month and then at Months 3, 6, 9, and 12. In Years 2 and 3, you will be called every 6 months.

The study staff will ask about your overall health. In the first phone call, you will also be asked about any side effects that may have occurred.

This is an investigational study. Dalteparin is commercially available and FDA approved for use in preventing VTE that may occur for other reasons. Those reasons include abdominal surgery; surgery for a hip fracture, hip replacement, or knee replacement; and illnesses causing patients to be unable to move around.

Dalteparin is also commercially available and FDA approved to treat VTE in cancer patients. However, it is investigational to use dalteparin to prevent VTE in cancer patients receiving chemotherapy.

Up to 87 patients will take part in this study. All will be enrolled at MD Anderson.

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.

Venous thromboembolism (VTE) defined by both symptomatic and asymptomatic VTE which includes deep venous thrombosis (DVT) and pulmonary embolism (PE) through clinical assessments and radiologic studies. All patients undergo bilateral lower extremity ultrasound every 2 months while on study (total of 3 exams including pre-randomization). VTE requires imaging documentation to evaluate use of prophylactic anticoagulation in reducing the occurrence of VTE in a patient population with a known high risk of VTE.

Eisai Inc.

Group 1: Dalteparin

Group 2: Control

Total

Age, Continuous

>=60

Age, Customized

Sex: Female, Male

Black or African American

Causacian

Hispanic

Other

Unknown or Unreported

Race/Ethnicity, Customized

United States

Region of Enrollment

Saroj Vadhan-Raj, MD/Professor, Sarcoma Medical Oncology

Number of Participants With Venous Thromboembolic Events (VTE)

No Dalteparin study drug (primary prophylaxis).

Overall Study

Acute Graft Versus Host Disease

dalteparin

Pfizer CT.gov Call Center

Three month treatment of acute VTE with Fragmin in pediatric cancer patients

Primary study objectives include are to determine the pharmacodynamic (PD) profiles for treatment doses of dalteparin in pediatric subjects of different ages with cancer and venous thromboembolism (VTE), using anti-Xa (Xa) levels and a population PD analysis methodology, and to determine the median dose required to achieve therapeutic anti- Xa levels (0.5 to 1.0 International Units \[IU\]/mL) based on subject age and weight.

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 international unit per milliliter (IU/mL). Cumulative data of Day 1 to 7 has been reported.

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Percentage of participants who achieved the prespecified level during the dose adjustment phase were reported in this outcome measure.

Symptomatic VTE defined as new or progressive signs and symptoms as judged by the investigator including but not limited to: objective swelling, pain or tenderness, pitting edema, erythema or cyanosis. Progression of VTE: Progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis.

It was defined as the time interval (in days) between date of first study treatment and date of documentation of first VTE. VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot breaks, loose and travels in the blood, this is called VTE. VTE was confirmed by at least one radiographic test and was defined as any new or progressive VTE whose signs and symptoms (identified by the investigator) included: objective swelling or tenderness, pitting edema, erythema or cyanosis.

VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. PE is a blood clot in the lungs. Clinical response of progression was defined as progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. Clinical response of regression: Regressed clot burden utilizing the same imaging modality as the screening visit. Clinical response of resolution: Thrombus resolution of the qualifying event measured by repeat imaging at the end of study (EOS) visit.

A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter 24 hours, Overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, Overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration or bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal). A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major or clinically relevant no major bleeding (bleeding resulting in any medical or surgical interventions but which did not meet the criteria for major bleeding).

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after the last dose of study drug (up to Day 132) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

Criteria:hematology:hemoglobin, hematocrit, erythrocytes less than(\<)0.8\*lower limit of normal(LLN), platelets \<0.5\*LLN \>1.75\*upper limit of normal (ULN),leukocytes \<0.6\* LLN \>1.5\* ULN, lymphocytes, lymphocytes/Leukocytes, neutrophils, neutrophils/leukocytes \<0.8\* LLN \>1.2\* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes \>1.2\*ULN, activated partial thromboplastin time, prothrombin time, prothrombin international normalized ratio \>1.1\* ULN. Clinical chemistry: bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase \>3.0\*ULN, protein, albumin \<0.8\* LLN \>1.2\* ULN, blood urea nitrogen, creatinine \>1.3\* ULN, sodium \<0.95\*LLN \>1.05\*ULN, potassium, chloride, calcium, magnesium \<0.9\* LLN \>1.1\* ULN, phosphate \<0.8\* LLN \>1.2\* ULN, glucose \<0.6\*LLN \>1.5\*ULN, estimated(est) creatinine clearance, est GFR modified and bedside schwartz, \>1.0\* ULN. Urinalysis: creatinine \>1.0\*ULN.

Heart rate and pulse rate of participants were measured in terms of beats per minute.

Respiratory rate was defined as the number of breaths per minute.

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported.

Time to first occurrence of major bleeding event was defined as the time interval (in days) between date of first study treatment and date of documentation of first major bleeding event. A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter, overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration, bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal or intraspinal).

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. The percentage of participants who had anti factor-Xa levels within the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure.

Prespecified therapeutic anti-factor Xa range was 0.5-1.0 IU/mL. The percentage of participants who had anti-factor Xa levels outside the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure.

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data for day 1 to 7 has been reported.

Time to achieve the target range (prespecified therapeutic anti- factor Xa levels) was defined as the number of days from the first dose of study drug to the final dose that achieves the target anti-factor Xa level. Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data of Day 1 to 7 is reported.

During dose adjustment phase, doses were adjusted according to prespecified therapeutic anti-Xa levels in order to achieve target prespecified therapeutic anti-factor Xa levels (0.5 to 1.0 IU/mL). Number of dose adjustments which were done within the specified time window of up to 4 hours post dose on all days (1 to 7) to achieve the prespecified therapeutic anti-Xa levels are reported.

Pfizer

Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.

Participants aged \>= 0 to \< 8 weeks were administered 125 IU/kg of dalteparin sodium injection subcutaneously twice daily from Day 1 to 7 in DA phase, Day 8 to 14 in PD phase and from Day 15 in FU phase (up to 104 days). Participants were to participate in the study for up to 104 days of study drug treatment to monitor the status of the qualifying VTE. Participants were followed up for safety for up to 28 days after last dose of study drug (up to 132 days).

Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)

Participants aged \>=8 weeks to \<2 years were administered 150 IU/kg of dalteparin sodium injection subcutaneously twice daily from Day 1 to 7 in DA phase, Day 8 to 14 in PD phase and from Day 15 in FU phase (up to 104 days). Participants were to participate in the study for up to 104 days of study drug treatment to monitor the status of the qualifying VTE. Participants were followed up for safety for up to 28 days after last dose of study drug (up to 132 days).

Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)

Participants aged \>=2 years to \<8 years were administered 125 IU/kg of dalteparin sodium injection subcutaneously twice daily from Day 1 to 7 in DA phase, Day 8 to 14 in PD phase and from Day 15 in FU phase (up to 104 days). Participants were to participate in the study for up to 104 days of study drug treatment to monitor the status of the qualifying VTE. Participants were followed up for safety for up to 28 days after last dose of study drug (up to 132 days).

Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)

Participants aged \>=8 years to \<12 years were administered 125 IU/kg of dalteparin sodium injection subcutaneously twice daily from Day 1 to 7 in DA phase, Day 8 to 14 in PD phase and from Day 15 in FU phase (up to 104 days). Participants were to participate in the study for up to 104 days of study drug treatment to monitor the status of the qualifying VTE. Participants were followed up for safety for up to 28 days after last dose of study drug (up to 132 days).

Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)

Participants aged \>=12 years to \<19 years were administered 100 IU/kg of dalteparin sodium injection subcutaneously twice daily from Day 1 to 7 in DA phase, Day 8 to 14 in PD phase and from Day 15 in FU phase (up to 104 days). Participants were to participate in the study for up to 104 days of study drug treatment to monitor the status of the qualifying VTE. Participants were followed up for safety for up to 28 days after last dose of study drug (up to 132 days).

Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)

Ethnicity (NIH/OMB)

Race (NIH/OMB)

The safety analysis set included all the participants who received at least 1 dose of study drug.

Pfizer ClinicalTrials.gov Call Center

All participants who received dalteparin sodium injection, subcutaneously at a dose of 100 to 150 IU/kg twice daily from Day 1 to 7 in dose adjustment phase, Day 8-14 in PD phase and from Day 15 in follow up phase until bleeding necessitating or unexpected permanent discontinuation of anticoagulation therapy, unexpected thrombocytopenia and other adverse event necessitating discontinuation of study drug (up to a maximum of 104 days). Participants were followed up for safety for up to 28 days after last dose of study drug (up to 132 days).

Dalteparin Sodium: All Participants (>= 0 to < 19 Years)

The pharmacodynamic (PD) analysis set included all participants who received at least 1 dose of study drug and achieved therapeutic range of anti-factor Xa during dose adjustment phase.

Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level

Analysis population included all the participants who received at least 1 dose of study drug.

Percentage of Participants Who Achieved Prespecified Therapeutic Anti- Factor Xa Levels

The PD analysis set included all participants who received at least 1 dose of study drug and achieved therapeutic range of anti-factor Xa during dose adjustment phase. Data for this outcome measure (OM) was not planned to be collected and analyzed for age group of \>=0 to \<8 weeks.

Number of Participants With New or Progressive Symptomatic Venous Thromboembolism (VTE)

The PD analysis set included all participants who received at least 1 dose of study drug and achieved therapeutic range of anti-factor Xa during dose adjustment phase.

Time to First Occurrence of Symptomatic Recurrent Venous Thromboembolism (VTE)

Progression

Regression

Resolution

No Change

The PD analysis set included all participants who received at least 1 dose of study drug and achieved therapeutic range of anti-factor Xa during dose adjustment phase. Data for this OM was not planned to be collected and analyzed for age group of \>=0 to \<8 weeks.

Percentage of Participants With Clinical Response of Progression, Regression, Resolution and No Change in Venous Thromboembolism (VTE)

Major Bleeding

Minor Bleeding

Percentage of Participants With Major and Minor Bleeding Event

SAEs

Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

The safety analysis set included all the participants who received at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure.

Number of Participants With Laboratory Abnormalities

SBP: Baseline

SBP: Day 1

SBP: Day 2

SBP: Day 30

SBP: Day 60

SBP: Day 90

DSBP: Baseline

DSBP: Day 1

DSBP: Day 2

DSBP: Day 30

DSBP: Day 60

DSBP: Day 90

The safety analysis set included all the participants who received at least 1 dose of study drug. Here "number analyzed" signifies the number of participants evaluable at specific time points.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization	NCT03407469	Cancer-related ...	Questionnaires	18 Years -	M.D. Anderson Cancer Center
Optimal Prophylactic Method of Venous Thromboembolism (VTE)	NCT01448746	Venous Thromboe...	low molecular w...	20 Years - 75 Years	The Catholic University of Korea
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients	NCT00966277	Pancreatic Canc... Venous Thromboe...	Dalteparin	18 Years -	M.D. Anderson Cancer Center
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients	NCT00952380	Venous Thromboe...	dalteparin	- 18 Years	Pfizer
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer	NCT00476216	Non-Small Cell ... Venous Thromboe...	Combination of ...	18 Years - 79 Years	University of Alabama at Birmingham
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients	NCT00952380	Venous Thromboe...	dalteparin	- 18 Years	Pfizer
Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer	NCT00660205	Thrombosis Deep Venous Thr... Pulmonary Embol... Venous Thromboe... Pancreas Cancer Esophagus Cance... Gastric Cancer		15 Years - 85 Years	University of Aarhus
Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer	NCT00660205	Thrombosis Deep Venous Thr... Pulmonary Embol... Venous Thromboe... Pancreas Cancer Esophagus Cance... Gastric Cancer		15 Years - 85 Years	University of Aarhus
Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans	NCT00925808	Cancer Venous Thromboe...	Questionnaires	18 Years -	M.D. Anderson Cancer Center
API-CAT STUDY for APIxaban Cancer Associated Thrombosis	NCT03692065	Cancer-associat...	Apixaban 5 MG	18 Years -	Assistance Publique - Hôpitaux de Paris
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)	NCT01524653	Venous Thromboe... Deep Vein Throm... Neoplasms	Rosuvastatin Placebo	18 Years -	University of Vermont
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer	NCT00476216	Non-Small Cell ... Venous Thromboe...	Combination of ...	18 Years - 79 Years	University of Alabama at Birmingham

Spots Global Cancer Trial Database for vte

Every month we try and update this database with for vte cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for vte

Every month we try and update this database with for vte cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for vte cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.